CARDENE IV (Nicardipine Hydrochloride) in 0: recall status
Notice names this product. Baxter Healthcare’s CARDENE IV (Nicardipine Hydrochloride) in 0 is named in FDA Class II recall D-0813-2026.
Your particular item is not yet verified. Compare the identifiers and exclusions in the notice before deciding whether it applies.Agency-reported hazard: CGMP Deviations Identifying details: Lot # NC177818, Exp Date: 12/31/2026; Lot # NC188869, Exp Date: 12/31/2027.. Units affected: N/A. Status: Ongoing.
1. Compare your item
This notice names a product; your particular item is not yet verified. Compare every applicable model, serial, lot, production-date or model-year boundary below.
Product named
CARDENE IV (Nicardipine Hydrochloride) in 0
Company / brand
Baxter Healthcare
Lot / serial / date codes
Lot # NC177818, Exp Date: 12/31/2026; Lot # NC188869, Exp Date: 12/31/2027.
Distribution
US Nationwide; Puerto Rico; and Chile.
Agency product description and boundaries
CARDENE IV (Nicardipine Hydrochloride) in 0.83% Sodium Chloride Injection, 40 mg in 200 mL (0.2 mg/mL) in GALAXY Single-Dose Container, Manufactured and Marketed by: Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 43066-016-10.
Still to verify: match the label on your item with the full official notice, including any exclusions, tables and photos. Some identifiers appear only on the agency website and are absent from this data feed. A missing field does not mean all versions are affected.
If your lot or date falls outside a stated range, this notice has not established that your item is affected. This is not a finding about other recalls or product safety.